The estimated Net Worth of Alexandria Forbes is at least $18.1 Million dollars as of 14 January 2024. Alexandria Forbes owns over 30,000 units of MeiraGTx plc stock worth over $5,788,087 and over the last 8 years he sold MGTX stock worth over $3,876,964. In addition, he makes $8,480,260 as President, Chief Executive Officer, and Director at MeiraGTx plc.
Alexandria has made over 15 trades of the MeiraGTx plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of MGTX stock worth $124,800 on 14 January 2024.
The largest trade he's ever made was exercising 173,750 units of MeiraGTx plc stock on 7 January 2024 worth over $722,800. On average, Alexandria trades about 26,960 units every 60 days since 2016. As of 14 January 2024 he still owns at least 1,391,367 units of MeiraGTx plc stock.
You can see the complete history of Alexandria Forbes stock trades at the bottom of the page.
Dr. Alexandria Forbes Ph.D. serves as President, Chief Executive Officer, Director of the Company. Prior to joining MeiraGTx, Dr. Forbes served as Senior Vice President of Commercial Operations at Kadmon Holdings, Inc., a biopharmaceutical company, from September 2013 to April 2015, and served as a member of its board of directors until June 2018. Prior to Kadmon Holdings, Inc., Dr. Forbes spent eleven years as a healthcare investor at Sivik Global Healthcare (formerly Argus Partners), a healthcare hedge fund, from August 2001 to November 2008, and at Meadowvale Asset Management, a healthcare hedge fund, from January 2010 to June 2012. Before entering the hedge fund industry, Dr. Forbes was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center from March 1997 to September 2000. Prior to this, Dr. Forbes was a research fellow at Duke University, and also at the Carnegie Institute at Johns Hopkins University. Dr. Forbes received an M.A. in Natural Sciences from Cambridge University and a Ph.D. in Molecular Genetics from Oxford University.
As the President, Chief Executive Officer, and Director of MeiraGTx plc, the total compensation of Alexandria Forbes at MeiraGTx plc is $8,480,260. There are no executives at MeiraGTx plc getting paid more.
Alexandria Forbes is 55, he's been the President, Chief Executive Officer, and Director of MeiraGTx plc since 2015. There are 12 older and 5 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.
Alexandria's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.
Over the last 6 years, insiders at MeiraGTx plc have traded over $7,031,523 worth of MeiraGTx plc stock and bought 9,222,038 units worth $85,317,799 . The most active insiders traders include Advisors Llcperceptive Life..., Joel S Marcus, and Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of $672,044. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth $5,000,000.
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
MeiraGTx plc executives and other stock owners filed with the SEC include: